您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。[港股财报]:吉林长龙药业年报 2022 - 发现报告
当前位置:首页/财报/招股书/报告详情/

吉林长龙药业年报 2022

2023-04-02港股财报墨***
吉林长龙药业年报 2022

2022Annual Report年報 CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the main board of the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.Given that the companies listed on the GEM are generally small and mid-sized companies, there is a risk that securities traded on the GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on the GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.This annual report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiaries (the “Group” and the “Directors”, respectively) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this annual report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this annual report misleading.香港聯合交易所有限公司(「聯交所」)GEM之特色GEM的定位,乃為中小型公司提供的市場,此等公司相比起其他在聯交所主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險,並應經過審慎周詳的考慮後方作出投資決定。由於GEM上市公司普遍為中小型公司,在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險,同時無法保證在GEM買賣的證券會有高流通量的市場。香港交易及結算所有限公司及聯交所對本報告之內容概不負責,對其準確性或完整性亦不發表任何聲明,並表明不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。本年度報告乃遵照聯交所GEM證券上市規則的規定而提供有關吉林省輝南長龍生化藥業股份有限公司及其附屬公司(「本集 團」)的資料,本公司各董事(「董事」)願共同及個別對此負全責。董事經作出一切合理查詢後確認,就彼等所知及所信,本年度報告所載資料在所有重大方面均準確完整及並無誤導或欺詐成分,及概無遺漏其他事宜,致使本年度報告中任何聲明或本年度報告存在誤導成分。 CONTENTS目錄3–4Corporate Information公司資料5–7Chairman’s Statement主席報告8–14Management Discussion and Analysis管理層討論及分析15–19Biographical Details of Directors and Senior Management董事及高級管理層簡歷20–28Report of the Directors董事會報告書29–36Corporate Governance Report企業管治報告37Report of the Supervisory Committee監事會報告書38–43Independent Auditor’s Report獨立核數師報告書44Consolidated Statement of Profit or Loss andOther Comprehensive Income綜合損益及其他全面收益表45–46Consolidated Balance Sheet綜合資產負債表47Consolidated Statement of Changes in Equity綜合權益變動表48–49Consolidated Statement of Cash Flows綜合現金流量表50–115Notes to the Consolidated Financial Statements綜合財務報表附註116Five-Year Financial Summary五年財務摘要 CORPORATE INFORMATION公司資料吉林省輝南長龍生化藥業股份有限公司二零二二年年報3BOARD OF DIRECTORSExecutive DirectorsMr. Zhang Hong (Chairman)Mr. Zhang Xiao GuangMr. Zhao Bao GangMr. Wu Guo WenMr. Zhang YiMr. Xu Xiang FuIndependent Non-Executive DirectorsMr. Gao Qi PinMs. Tian JieMr. Bai Jun GuiSUPERVISORSMr. Wang Ying XuMr. Yan Li YuMs. Qiao Xiao ChunCOMPLIANCE OFFICERMr. Zhang HongAUTHORIZED REPRESENTATIVESMr. Zhang HongMr. Zhao Bao GangAUDITORSPrism Hong Kong and Shanghai LimitedCertified Public AccountantsHong KongAUDIT COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinREMUNERATION COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Hong董事會執行董事張弘先生(主席)張曉光先生趙寶剛先生吳國文先生張翼先生徐向夫先生獨立非執行董事高其品先生田傑女士白君貴先生監事王英旭先生鄢禮玉先生喬曉春女士監察主任張弘先生授權代表張弘先生趙寶剛先生核數師上會栢誠會計師事務所有限公司執業會計師香港審核委員會白君貴先生田傑女士高其品先生薪酬委員會白君貴先生田傑女士高其品先生張弘先生 CORPORATE INFORMATION公司資料Jilin Province Huinan Changlong Bio-pharmacy Company LimitedANNUAL REPORT 20224公司秘書兼合資格會計師 莫世昌先生,CPA, FCCA提名委員會白君貴先生田傑女士高其品先生張曉光先生H股過戶登記處 香港證券登記有限公司香港皇后大道東183號合和中心17M主要往來銀行中國工商銀行輝南縣支行中國吉林省通化市香港主要營業地點香港九龍旺角彌敦道625及639號雅蘭中心辦公樓二期11樓1101–2室股份代號8049法定地址中國吉林省通化市輝南縣朝陽鎮北山街31號網址http://www.jlchanglong.comCOMPANY SECRETARY AND QUALIFIED ACCOUNTANTMr. Mok Sai Cheong Mark, CPA, FCCANOMINATION COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Xiao GuangH SHARE SHARE REGISTRAR AND TRANSFER OFFICEHong Kong Registrars Limited17M FloorHopewell Centre183 Queen’s Road EastHong KongPRINCIPAL BANKERIndustrial and Commercial Bank of ChinaHuinan County BranchTonghuaJilin ProvincePRCPRINCIPAL PLACE OF BUSINESS IN HONG KONGRoom 1101–2, 11/FOffice Tower Two, Grand Plaza625 & 639 Nathan RoadMong Kok, KowloonHong KongSTOCK CODE8049LEGAL ADDRESS31 Beishan StreetChaoyang TownHuinan CountyTonghuaJilin ProvincePRCWEBSITE ADDRESShttp://www.jlchanglong.com CHAIRMAN’S STAT

你可能感兴趣

hot

吉林长龙药业年报 2023

港股财报2024-03-28
hot

吉林长龙药业年报 2021

港股财报2022-04-29
hot

吉林长龙药业年报 2020

港股财报2021-03-31